Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CMPS Stock Forecast 2026-2027
$6.66
Current Price
$898.59M
Market Cap
Buy 11
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to CMPS Price Targets
+951.1%
To High Target of $70.00
+177.8%
To Median Target of $18.50
+20.1%
To Low Target of $8.00
CMPS Price Momentum
+20.4%
1 Week Change
+16.2%
1 Month Change
+112.8%
1 Year Change
-3.5%
Year-to-Date Change
-25.2%
From 52W High of $8.90
+196.0%
From 52W Low of $2.25
📊 TOP ANALYST CALLS
Did CMPS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Compass Pathways is one of their latest high-conviction picks.
Latest CMPS Stock Price Targets & Analyst Predictions
Based on our analysis of 15 Wall Street analysts, CMPS has a bullish consensus with a median price target of $18.50 (ranging from $8.00 to $70.00). The overall analyst rating is Strong Buy (9.2/10). Currently trading at $6.66, the median forecast implies a 177.8% upside. This outlook is supported by 11 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Patrick R. Trucchio at HC Wainwright & Co., projecting a 951.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CMPS Analyst Ratings
11
Buy
1
Hold
0
Sell
CMPS Price Target Range
Low
$8.00
Average
$18.50
High
$70.00
Current: $6.66
Latest CMPS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CMPS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 26, 2026 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $18.00 |
| Mar 25, 2026 | Morgan Stanley | Vikram Purohit | Overweight | Maintains | $16.00 |
| Mar 2, 2026 | HC Wainwright & Co. | Patrick R. Trucchio | Buy | Maintains | $70.00 |
| Feb 18, 2026 | RBC Capital | Leonid Timashev | Outperform | Maintains | $22.00 |
| Feb 18, 2026 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $20.00 |
| Feb 18, 2026 | Morgan Stanley | Vikram Purohit | Overweight | Maintains | $18.00 |
| Jan 23, 2026 | RBC Capital | Leonid Timashev | Outperform | Maintains | $21.00 |
| Nov 5, 2025 | Morgan Stanley | Vikram Purohit | Overweight | Maintains | $11.00 |
| Oct 13, 2025 | BTIG | Thomas Shrader | Buy | Maintains | $14.00 |
| Aug 4, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Maintains | $40.00 |
| Aug 1, 2025 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $15.00 |
| Jul 15, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $45.00 |
| Jul 15, 2025 | HC Wainwright& Co. | Buy | Reiterates | $N/A | |
| Jun 23, 2025 | Evercore ISI Group | Josh Schimmer | In-Line | Downgrade | $6.00 |
| May 27, 2025 | Cantor Fitzgerald | Josh Schimmer | Overweight | Assumes | $12.00 |
| May 12, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $45.00 |
| Mar 28, 2025 | Cantor Fitzgerald | Charles Duncan | Overweight | Reiterates | $N/A |
| Mar 4, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $45.00 |
| Feb 28, 2025 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $15.00 |
| Feb 27, 2025 | Stifel | Paul Matteis | Buy | Initiates | $11.00 |
Compass Pathways plc Depositary Receipt (CMPS) Competitors
The following stocks are similar to Compass Pathways based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Compass Pathways plc Depositary Receipt (CMPS) Financial Data
Compass Pathways plc Depositary Receipt has a market capitalization of $898.59M with a P/E ratio of -2.2x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -565.3%.
Valuation Metrics
Market Cap
$898.59M
Enterprise Value
$744.06M
P/E Ratio
-2.2x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+17.4%
Current Ratio
0.8x
Debt/Equity
-0.7x
ROE
-565.3%
ROA
-51.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Compass Pathways plc Depositary Receipt (CMPS) Business Model
About Compass Pathways plc Depositary Receipt
What They Do
Develops innovative therapies for mental health.
Business Model
The company focuses on developing proprietary synthetic psilocybin therapies, specifically COMP360, which is designed to treat mental health conditions such as treatment-resistant depression, PTSD, and anorexia nervosa. Revenue is generated through the advancement of its therapies in clinical trials, with potential future income from product sales upon regulatory approval.
Additional Information
Founded in 2020 and based in London, Compass Pathways is at the forefront of the psychedelic medicine sector, addressing significant gaps in mental health treatment. Its emphasis on evidence-based approaches positions it well within an evolving market for alternative psychiatric therapies.
Company Information
Sector
Healthcare
Industry
Medical Care Facilities
Employees
156
CEO
Mr. Kabir Kumar Nath M.A., M.B.A.
Country
United Kingdom
IPO Year
2020
Website
compasspathways.comCompass Pathways plc Depositary Receipt (CMPS) Latest News & Analysis
Latest News
Quick Summary
Compass Pathways (Nasdaq: CMPS) supports the White House's Executive Order to accelerate medical treatments for serious mental illness, highlighting the potential of FDA-approved psychedelics.
Why It Matters
The White House's Executive Order supports psychedelics for mental health, enhancing potential for regulatory approvals and market growth, positively impacting Compass Pathways' stock outlook.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Compass Pathways plc (Nasdaq: CMPS) invites U.S. organizations to apply for a grant to develop training for healthcare providers on investigational COMP360 psilocybin treatment, pending approval.
Why It Matters
Compass Pathways' grant invitation for training in psilocybin treatment signals potential FDA approval and market expansion, which could enhance revenue and investor confidence in the biotech sector.
Source: Business Wire
Market Sentiment:
Neutral
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12 days ago
Quick Summary
Compass Pathways plc (Nasdaq: CMPS) granted equity awards under its 2026 Inducement Plan to seven new non-executive employees, totaling 117,445 shares in options and restricted units.
Why It Matters
The equity awards signal confidence in new hires, potentially enhancing innovation and growth. This could positively impact CMPS's market position and share value.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Compass Pathways plc (Nasdaq: CMPS) will participate in the Needham Virtual Healthcare Conference on April 14, 2026, with a fireside chat at 12:45 pm ET. A live webcast will be available online.
Why It Matters
Compass Pathways' participation in the Needham Virtual Healthcare Conference highlights its commitment to mental health innovation, potentially influencing investor confidence and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Compass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights
26 days ago
Quick Summary
Compass Pathways plc (Nasdaq: CMPS) reported Q4 and full-year 2025 financial results, highlighting progress with COMP360 in advancing mental healthcare and psychiatric treatment options.
Why It Matters
Compass Pathways' financial results and advancements in mental healthcare highlight its role in a growing market, potentially impacting stock performance and investor sentiment in biotech.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Compass Pathways plc (Nasdaq: CMPS) will attend the Stifel 2026 Virtual CNS Forum on March 17-18, 2026, participating in a fireside chat on March 18 at 10:30am ET. A live webcast will be available.
Why It Matters
Compass Pathways' participation at a major CNS forum highlights its commitment to innovation in mental health, potentially influencing investor sentiment and stock performance in the biotech sector.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About CMPS Stock
What is Compass Pathways plc Depositary Receipt's (CMPS) stock forecast for 2026?
Based on our analysis of 15 Wall Street analysts, Compass Pathways plc Depositary Receipt (CMPS) has a median price target of $18.50. The highest price target is $70.00 and the lowest is $8.00.
Is CMPS stock a good investment in 2026?
According to current analyst ratings, CMPS has 11 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $6.66. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CMPS stock?
Wall Street analysts predict CMPS stock could reach $18.50 in the next 12 months. This represents a 177.8% increase from the current price of $6.66. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Compass Pathways plc Depositary Receipt's business model?
The company focuses on developing proprietary synthetic psilocybin therapies, specifically COMP360, which is designed to treat mental health conditions such as treatment-resistant depression, PTSD, and anorexia nervosa. Revenue is generated through the advancement of its therapies in clinical trials, with potential future income from product sales upon regulatory approval.
What is the highest forecasted price for CMPS Compass Pathways plc Depositary Receipt?
The highest price target for CMPS is $70.00 from Patrick R. Trucchio at HC Wainwright & Co., which represents a 951.1% increase from the current price of $6.66.
What is the lowest forecasted price for CMPS Compass Pathways plc Depositary Receipt?
The lowest price target for CMPS is $8.00 from at , which represents a 20.1% increase from the current price of $6.66.
What is the overall CMPS consensus from analysts for Compass Pathways plc Depositary Receipt?
The overall analyst consensus for CMPS is bullish. Out of 15 Wall Street analysts, 11 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $18.50.
How accurate are CMPS stock price projections?
Stock price projections, including those for Compass Pathways plc Depositary Receipt, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 19, 2026 3:16 PM UTC